Orthognathic maxillofacial surgery. Congenital malformation syndromes predominantly affecting facial appearance
Conditions
Interventions
Intervention 1: First group received Tranexamic acid in saline solution (1000 miligrams of tranexamic acid in 1000 cc of IV-normal saline) as the irrigant liquid during operation. Intervention 2: S
Treatment - Drugs
Placebo
First group received Tranexamic acid in saline solution (1000 miligrams of tranexamic acid in 1000 cc of IV-normal saline) as the irrigant liquid during operation.
Second group received Normal-saline (placebo) solution as the irrigant liquid during operation.
Sponsors
Shiraz University Of Medical Sciences
Eligibility
Sex/Gender
All
Age
15 Years to 45 Years
Inclusion criteria
Inclusion criteria: Participants including major eligibility criteria: The patients with a history of heart disease - drug allergy - those with history of taking drugs that interacts with coagulation - kidney disease and age over 45 years and under 15 years old are excluded.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hemoglobin and Hematocrit Level. Timepoint: Pre and Post-Operation. Method of measurement: Lab. data.;Blood loss during operation. Timepoint: End of surgery. Method of measurement: Direct observation of surgical gauzes, weight of gauzes, estimation of blood in the surgical suction.;Duration of operation. Timepoint: End of surgery. Method of measurement: minute.;Blood Fibrinogen Level. Timepoint: Pre and Post-Operation. Method of measurement: Lab. data. | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood product consumption. Timepoint: End of operation. Method of measurement: ml.;Side effect of Tranexamic Acid. Timepoint: End of operation. Method of measurement: Case report. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactRoholah Vahedi
Dental School Of Shiraz University Of Medical Sciences
Outcome results
None listed